NASDAQ:TRIB

Trinity Biotech Q1 2026 Earnings Results & Report

Trinity Biotech logo
$6.01 +0.63 (+11.71%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$5.71 -0.30 (-4.99%)
As of 07:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trinity Biotech beat analyst expectations on both earnings and revenue in its Q1 2026 results, released June 16, 2026. The company reported EPS of -$6.90 versus the -$9.30 consensus estimate, while revenue of $10.85 million topped the $10.68 million estimate by $168.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Trinity Biotech EPS Results

Actual EPS
-$6.90
Consensus EPS
-$9.30
Beat/Miss
Beat by +$2.40
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Trinity Biotech Revenue Results

Actual Revenue
$10.85 million
Expected Revenue
$10.68 million
Beat/Miss
Beat by +$168.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Trinity Biotech's Q2 2026 earnings is estimated for Thursday, December 10, 2026, based on past reporting schedules

Earnings Documents

Trinity Biotech Q1 2026 Earnings FAQ

Trinity Biotech (NASDAQ:TRIB) reported earnings of -$6.90 per share for Q1 2026, beating the consensus estimate of -$9.30. The report was announced on Tuesday, June 16, 2026.

Trinity Biotech reported revenue of $10.85 million for Q1 2026, against a consensus estimate of $10.68 million.

Trinity Biotech's next earnings date is estimated for Thursday, December 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Trinity Biotech on the company's earnings history page.

Trinity Biotech Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Trinity Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trinity Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trinity Biotech and other key companies, straight to your email.

About Trinity Biotech

Trinity Biotech (NASDAQ:TRIB) is an Irish diagnostics company that develops, manufactures and markets products for point-of-care testing and clinical laboratories. Its offerings include rapid tests for infectious diseases such as HIV, as well as laboratory assays used in areas including diabetes care.

The company also provides products for monitoring blood glucose and assessing long-term blood sugar control. Trinity Biotech serves customers in multiple international markets through a combination of direct sales and distribution partners.

View Trinity Biotech Profile